Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus NAQUIVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus NAQUIVAL.
EDARBYCLOR vs NAQUIVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Thiazide Diuretic Combination